Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)

Abstract

Renal cell carcinoma (RCC) is the most common renal cancer, and has a poor prognosis in individuals with metastases (mRCC). In this report, we describe a 48-year-old woman with unresectable multiple liver metastases and a colonic metastasis of RCC who was treated with sunitinib in combination with hepatic microwave ablation and obtained a clinical and pathological complete remission. We consider that sunitinib combined with microwave ablation can prevent unresectable hepatic metastases of RCC from evolving, and that sunitinib alone can achieve clinical and pathological remission in patients with colonic metastasis of RCC.

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

“…[110] And, within the context of LVM-RCC, MWA has been indicated to offer several practical benefits over other techniques, including a larger ablation volume, shorter surgical time, and a reduced heat-sink effect, without an increase in recurrence rate. [111] Moreover, the study by Peng et al has shown that the integration of sunitinib with MWA effectively prevents the progression of unresectable LVM-RCC, [112] suggesting that the combination of targeted pharmacotherapy with ablation technology holds potential for novel therapeutic avenues.…”